Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $39.2 million versus the consensus estimate of $40.61 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.